Raymond James Downgrades Jounce Therapeutics to Outperform, Lowers Price Target to $3
Raymond James analyst Steven Seedhouse downgrades Jounce Therapeutics (NASDAQ:JNCE) from Strong Buy to Outperform and lowers the price target from $16 to $3.